Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Rhythm Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Rhythm Pharmaceuticals şirketinin toplam hissedar öz sermayesi $179.5M ve toplam borcu $108.4M olup, bu da borç-öz sermaye oranını 60.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $381.8M ve $202.4M dir.
Anahtar bilgiler
60.4%
Borç/özkaynak oranı
US$108.37m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$319.13m |
| Eşitlik | US$179.50m |
| Toplam yükümlülükler | US$202.35m |
| Toplam varlıklar | US$381.85m |
Son finansal sağlık güncellemeleri
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Recent updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: RYTM 'nin kısa vadeli varlıkları ( $357.4M ) kısa vadeli yükümlülüklerini ( $54.7M ) aşıyor.
Uzun Vadeli Yükümlülükler: RYTM şirketinin kısa vadeli varlıkları ( $357.4M ) uzun vadeli yükümlülüklerini ( $147.6M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: RYTM şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: RYTM şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 60.4% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: RYTM şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.
Tahmini Nakit Akışı: RYTM tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.